Sofgen Pharma S.A (PROCF) Fair Value & Analysis
Healthcare · US · Market cap $58.4M
Sofgen Pharma S.A
PROCF · US
Fair value as of: Jul 31, 2026
From 3 valuation models · updated 10 days ago
Share price −98.8% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (4 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 31, 2026.
How to read this chart
4‑month range $0.0251 – $2.10 · fair‑value band $0.0195 – $0.0252 · the $0.0251 price screens below the $0.0255 fair value. As of Jul 31, 2026.
Analysis
Sofgen Pharma S.A (PROCF) currently trades at $0.0251, while our model-based Fair Value estimate is $0.0255, implying the stock looks roughly 1.6% fairly valued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Sofgen Pharma S.A generated revenue of $374M at a net margin of -18.3%. Revenue grew 7.3% year over year. Net debt stands at $276M. Fundamentals as of Jul 31, 2026
Our scenario range runs from $0.0195 (bear case) to $0.0252 (bull case); at $0.0251, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 2%, PROCF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Notify me when PROCF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics.
Full company description
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands; and Softgel pharmaceutical products, such as Advil, Apronax Liquidgels, multivitamins, Vitamin D, and Dolex ActivGel. It also formulates, manufactures, and markets branded prescription drugs in therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory; and manufactures and markets personal high-complexity drugs for hospital use comprising antibiotics, blood clot, immunosuppressant, oncology, and analgesics products. In addition, the company develops, manufactures, and markets OTC consumer healthcare products consisting of gastrointestinal, skin care, cough and cold, analgesics, urological, and vitamin, minerals, and supplements, as well as antibiotics, anti-infective, and anti-parasitic. Further, it offers blood glucose meters, telemonitoring, Rx oral anti-diabetics products, insulin delivery systems, and other diabetes solutions; and syringes, double chamber syringes, injection vials, injection ampoules, sterilized powder products, sterile droppers, and lyophilized solid vials. The company was formerly known as Procaps Group S.A. Sofgen Pharma S.A. was founded in 1977 and is based in Luxembourg, Luxembourg.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2024 · reported fiscal years
Sofgen Pharma S.A reported revenue of $374M in FY2024 versus $404M in FY2021, a compound −2.5%/yr. Reported net income was −$68.3M in FY2024.
Watch PROCF: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Sofgen Pharma S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sofgen Pharma S.A (PROCF) overvalued or undervalued?
What is the fair value of PROCF?
What is the quality score of PROCF?
What is the revenue of Sofgen Pharma S.A (PROCF)?
What is the net profit margin of PROCF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sofgen Pharma S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.